Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Irofulven hydroxymethylacylfulvene: MOGN started an international Phase I trial of irofulven plus capecitabine in 40 patients with advanced solid tumors

MGI Pharma Inc. (MOGN), Minneapolis, Minn.

Read the full 67 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE